AMEX:OCX

Stock Analysis Report

Executive Summary

OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has OncoCyte's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OCX

3.1%

US Biotechs

1.8%

US Market


1 Year Return

-9.1%

OCX

-7.9%

US Biotechs

7.3%

US Market

Return vs Industry: OCX underperformed the US Biotechs industry which returned -7.9% over the past year.

Return vs Market: OCX underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

OCXIndustryMarket
7 Day0%3.1%1.8%
30 Day-23.4%-2.4%-0.7%
90 Day-17.5%-0.8%0.06%
1 Year-9.1%-9.1%-7.1%-7.9%9.7%7.3%
3 Year-60.5%-60.5%14.2%10.3%46.3%36.9%
5 Yearn/a0.07%-4.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is OncoCyte's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OncoCyte undervalued compared to its fair value and its price relative to the market?

2.64x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate OCX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate OCX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OCX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OCX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate OCX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCX is overvalued based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is OncoCyte forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

27.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OCX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OCX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if OCX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if OCX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: OCX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has OncoCyte performed over the past 5 years?

-24.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: OCX is unprofitable, and losses have increased over the past 5 years at a rate of -24.3% per year.

Accelerating Growth: Unable to compare OCX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: OCX has a negative Return on Equity (-49.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: OCX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: OCX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is OncoCyte's financial position?


Financial Position Analysis

Short Term Liabilities: OCX's short term assets ($37.1M) exceeds its short term liabilities ($4.1M)

Long Term Liabilities: OCX's short term assets (37.1M) exceeds its long term liabilities (100.0K)


Debt to Equity History and Analysis

Debt Level: OCX's debt to equity ratio (2.3%) is considered satisfactory

Reducing Debt: Insufficient data to determine if OCX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: OCX has a low level of unsold assets or inventory.

Debt Coverage by Assets: OCX's debt is covered by short term assets (assets are 48.197650x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OCX has sufficient cash runway for 1.880777 years if free cash flow continues to reduce at historical rates of -22.8% each year.


Next Steps

Dividend

What is OncoCyte's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate OCX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OCX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if OCX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of OncoCyte's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Ronnie, Ron Andrews (59yo)

0.3yrs

Tenure

US$151,184

Compensation

Mr. Ronald A. Andrews, Jr., also known as Ronnie or Ron, has been Chief Executive Officer and President of OncoCyte Corporation since July 1, 2019 and is its Director since April 2018. Mr. Andrews has been ...


Management Age and Tenure

0.8yrs

Average Tenure

66yo

Average Age

Experienced Management: OCX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

2.4yrs

Average Tenure

59yo

Average Age

Experienced Board: OCX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: OCX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$108,13018 Sep 19
Andrew Arno
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares50,000
Max PriceUS$2.16
BuyUS$19,80016 Sep 19
Tony Kalajian
EntityIndividual
Role
Chief Accounting Officer
SVP & Chief Accounting Officer
Shares10,000
Max PriceUS$1.98
SellUS$6,640,00013 Sep 19
Lineage Cell Therapeutics, Inc.
EntityCompany
Shares4,000,000
Max PriceUS$1.66
BuyUS$3,320,00013 Sep 19
Broadwood Capital, Inc.
EntityCompany
Shares2,000,000
Max PriceUS$1.66
BuyUS$20,06012 Sep 19
Mitchell Levine
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max PriceUS$2.01
SellUS$4,500,00005 Jul 19
Lineage Cell Therapeutics, Inc.
EntityCompany
Shares2,250,000
Max PriceUS$2.00
BuyUS$2,000,00002 Jul 19
Broadwood Capital, Inc.
EntityCompany
Shares1,000,000
Max PriceUS$2.00
BuyUS$1,999,99912 Feb 19
Broadwood Capital, Inc.
EntityCompany
Shares533,333
Max PriceUS$3.75

Ownership Breakdown


Management Team

  • Judith Segall (66yo)

    Secretary

    • Tenure: 0yrs
  • Mike West (66yo)

    Scientific Advisor

    • Tenure: 4yrs
    • Compensation: US$328.84k
  • Mitch Levine

    Chief Financial Officer

    • Tenure: 1.9yrs
    • Compensation: US$873.30k
  • Ronnie, Ron Andrews (59yo)

    CEO, President & Director

    • Tenure: 0.3yrs
    • Compensation: US$151.18k
  • Lyndal Hesterberg

    Chief Scientific Officer

    • Tenure: 0.6yrs
    • Compensation: US$850.58k
  • Al Parker

    Chief Operating Officer

    • Tenure: 1.2yrs
  • Padma Sundar

    Senior Vice President of Marketing & Market Access

    • Tenure: 0.4yrs
  • Tony Kalajian

    SVP & Chief Accounting Officer

    • Tenure: 0.8yrs

Board Members

  • Andy Arno (60yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$137.56k
  • Al Kingsley (76yo)

    Director

    • Tenure: 10.1yrs
    • Compensation: US$118.81k
  • Ronnie, Ron Andrews (59yo)

    CEO, President & Director

    • Tenure: 0.3yrs
    • Compensation: US$151.18k
  • Cavan Redmond (58yo)

    Independent Chairman of the Board

    • Tenure: 1.5yrs
    • Compensation: US$155.34k
  • Melinda Griffith (64yo)

    Independent Director

    • Tenure: 0.3yrs
  • Andy Last (59yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$142.56k
  • Thomas Bauer

    Member of Medical Advisory Board

    • Tenure: 2.4yrs
  • Adi Mohanty (52yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: US$8.75k
  • D. Hogarth

    Member of Medical Advisory Board

    • Tenure: 2.4yrs
  • Ned Patz

    Member of Medical Advisory Board

    • Tenure: 2.4yrs

Company Information

OncoCyte Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OncoCyte Corporation
  • Ticker: OCX
  • Exchange: AMEX
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$88.354m
  • Shares outstanding: 51.97m
  • Website: https://www.oncocyte.com

Number of Employees


Location

  • OncoCyte Corporation
  • 1010 Atlantic Avenue
  • Suite 102
  • Alameda
  • California
  • 94501
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OCXAMEX (NYSE MKT LLC)YesCommon SharesUSUSDDec 2015
7OCDB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2015

Biography

OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive mol ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:16
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.